Monitor for Phase 2 RENEW trial interim data in Q4 2026, which could significantly impact stock price. The IPO provides critical funding but introduces substantial dilution (shares outstanding more than double). Watch for post-offering price stabilization and any insider selling lock-up expiration.
Executive Summary
Rein Therapeutics, a clinical-stage biopharmaceutical company focused on orphan pulmonary and fibrosis indications, filed an S-1 to offer 30 million shares of common stock at $1.66 per share, raising approximately $48 million net proceeds. The company has no approved products, reported $3.2 million in cash as of December 2025, and has a going concern qualification. Proceeds will fund working capital and repay $5.375 million in notes, extending runway through at least April 2027.
Key Financial Metrics
Key Facts
- Offering 30,000,000 shares at assumed price of $1.66 per share (last sale on April 24, 2026).
- Net proceeds estimated at approximately $48 million after expenses and note repayment.
- Lead candidate LTI-03 is in Phase 2 RENEW trial for idiopathic pulmonary fibrosis; top-line interim data expected Q4 2026.
- Cash and cash equivalents of $3.2 million and working capital deficit of $1.9 million as of December 31, 2025.
- Accumulated deficit of $401.3 million; going concern qualification in audited financial statements.
Financial Impact
Gross proceeds of approximately $49.8 million; net proceeds ~$48 million after expenses and repayment of $5.375 million notes.
Risk Factors
- Clinical trial failure or delay for LTI-03/other candidates.
- Going concern risk if IPO proceeds are insufficient to fund operations through key milestones.
- Shareholder dilution: post-offering shares increase from 28M to 58M (107% increase).
- No approved products or revenue; history of operating losses.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001193125-26-187803 |
| Document: d83075dex11.htm | 0001193125-26-187803 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 7w ago | Press Release | $0.8891 | awaiting T+60 | — | $0.5832 (−34.41%) |
Aug 14, 2026 10w ago | Press Release | $0.8060 | awaiting T+60 | — | $0.5832 (−27.64%) |
Jul 21, 2026 13w ago | Press Release | $0.8948 $0.7546 | ▼ −15.67% | ▼ −19.64% | $0.5832 (−34.82%) |
Jun 8, 2026 20w ago | DEFA14A | $0.9487 $0.7527 | ▼ −20.66% | ▼ −23.71% | $0.5832 (−38.53%) |
May 4, 2026 25w ago | 8-K | $1.02 $0.7680 | ▲ +24.71% | ▲ +27.45% | $0.5832 (+42.82%) |
May 4, 2026 25w ago | 424B5 | $1.02 $0.7580 | ▲ +25.69% | ▲ +27.54% | $0.5832 (+42.82%) |
May 1, 2026 25w ago | Press Release | $1.03 $0.7818 | ▲ +24.10% | ▲ +27.17% | $0.5832 (+43.38%) |
Apr 29, 2026 25w ago | Press Release | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.5832 (−54.26%) |
Apr 28, 2026 25w ago | S-1 | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.5832 (−54.26%) |
Apr 27, 2026 26w ago | 10-K/A | $1.49 $0.8400 | ▼ −43.62% | ▼ −48.40% | $0.5832 (−60.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers